Ocugen, Inc.
11 Great Valley Parkway
Malvern
PA
19355
United States
Tel: 720-859-3549
Website: http://ocugen.com/
250 articles about Ocugen, Inc.
-
Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
11/29/2023
Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL.
-
Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease
11/10/2023
Ocugen, Inc. today announced that the first patient has been dosed in its Phase 1/2 GARDian clinical trial for OCU410ST (AAV5- hRORA ).
-
Ocugen Provides Business Update with Third Quarter 2023 Financial Results
11/9/2023
Ocugen, Inc. reported third quarter 2023 financial results along with a general business update.
-
Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit
11/7/2023
Ocugen, Inc. today announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Dry AMD Therapeutic Development Summit, which is being held November 14-16, 2023.
-
A recent report by Tufts Medical Center reveals impressive approval rates for durable cell and gene therapies, but experts urge caution over persistent safety and accessibility concerns.
-
Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results
11/2/2023
Ocugen, Inc. announced that it will host a conference call and live webcast to discuss the Company’s third quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Thursday, November 9, 2023.
-
Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials
10/10/2023
Ocugen, Inc. announced that the National Institute of Allergy and Infectious Diseases, a part of the National Institutes of Health, will conduct a trial comparing the administration of Ocugen’s mucosal vaccine candidate, OCU500, via two different mucosal routes, inhalation into the lungs and as a nasal spray.
-
Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa
10/4/2023
Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the 2023 Cell & Gene Meeting on the Mesa being held October 10-12, 2023 in Carlsbad, CA at the Park Hyatt Aviara Resort.
-
Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference
9/29/2023
Ocugen, Inc. announced that Arun Upadhyay, PhD, Ocugen’s Chief Scientific Officer, Head of Research, Development and Medical, will be among the featured speakers at the 4th Annual Gene Therapy for Ophthalmic Disorders conference, which is being held October 3-5, 2023 in Boston, Mass.
-
Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference
9/27/2023
Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder and Dr. Huma Qamar, MPH, CMI, Head of Clinical Development and Medical Affairs will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst at the Chardan 7th Annual Genetic Medicines Conference being held October 2-3, 2023 in NYC.
-
Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board
9/21/2023
Ocugen, Inc. today announced that Connie Collingsworth, former Chief Operating Officer of the Bill and Melinda Gates Foundation, will join the Company’s Business Advisory Board (BAB).
-
Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023
9/20/2023
Ocugen, Inc. today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will participate in a panel at the annual Cantor Fitzgerald Global Healthcare Conference taking place from September 26-28, 2023 in NYC.
-
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
9/13/2023
Ocugen, Inc. today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial to assess the safety and efficacy of OCU400 for RP associated with NR2E3 and Rhodopsin (RHO) mutations and Leber congenital amaurosis (LCA) with mutation(s) in the CEP290 gene.
-
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
9/12/2023
Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, announced that it will host an Investor and Analyst Event on September 13, 2023 at 8:30 a.m. ET.
-
Ocugen Provides Business Update with Second Quarter 2023 Financial Results
8/21/2023
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today reported second quarter 2023 financial results along with a general business update.
-
Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results
8/18/2023
Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN) today announced that it will host a conference call and live webcast to discuss the Company’s second quarter 2023 financial results and provide a business update at 8:30 a.m. ET on Tuesday, August 22, 2023.
-
Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly
6/30/2023
Ocugen, Inc. today announced that the Company’s Chairman, CEO and Co-Founder will present at the American Association of Physicians of Indian Origin (AAPI) Convention and Scientific Assembly, July 6 – 9, 2023 in Philadelphia, PA.
-
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
6/9/2023
Ocugen, Inc. announced that the Company’s 2023 Annual Meeting of Shareholders was convened and adjourned, without any business being conducted, due to lack of the required quorum.
-
Ocugen, Inc. Announces Business Advisory Board
6/5/2023
Ocugen, Inc. announced that the Company has established a Business Advisory Board to assist in driving public/private partnerships with governments around the world; pursuing business collaborations, partnerships, and licensing opportunities; creating awareness of the Company’s differentiated capabilities; and promoting access to the Company’s therapies around the world.
-
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
5/24/2023
Ocugen, Inc. today announced the pricing of its underwritten public offering of 30,000,000 shares of its common stock for gross proceeds of $16.5 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ocugen.